公开(公告)号：US20150266976A1

公开(公告)日：2015-09-24

申请号：US14664750

申请日：2015-03-20

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Robert Babb ,  Ashique Rafique ,  Tammy T. Huang ,  Ergang Shi ,  Lynn Macdonald ,  Andrew J. Murphy

IPC分类号： C07K16/44 ,  G01N33/68 ,  A01K67/027

CPC分类号： C07K16/44 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/01 ,  C07K16/00 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/515 ,  C07K2317/569 ,  C07K2317/62 ,  C07K2317/92 ,  C12N15/8509 ,  G01N33/6854

摘要： Methods for making, identifying, isolating and/or making binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Exemplary binding proteins specific to small molecules are also provided.

摘要翻译： 提供了制备，鉴定，分离和/或制备含有免疫球蛋白轻链可变结构域的结合蛋白的方法，其包括与重链恒定区融合的体细胞超突变轻链可变结构域。 还提供了对小分子特异性的示例性结合蛋白。

公开(公告)号：US20210009698A1

公开(公告)日：2021-01-14

申请号：US16774945

申请日：2020-01-28

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： Sean Stevens ,  Tammy T. Huang ,  Joel H. Martin ,  Jeanette L. Fairhurst ,  Ashique Rafique ,  Eric Smith ,  Kevin J. Pobursky ,  Nicholas J. Papadopoulos ,  James P. Fandl ,  Gang Chen ,  Margaret Karow

IPC分类号： C07K16/28

摘要： A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.

公开(公告)号：US10584173B2

公开(公告)日：2020-03-10

申请号：US16119695

申请日：2018-08-31

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： Sean Stevens ,  Tammy T. Huang ,  Joel H. Martin ,  Jeanette L. Fairhurst ,  Ashique Rafique ,  Eric Smith ,  Kevin J. Pobursky ,  Nicholas J. Papadopoulos ,  James P. Fandl ,  Gang Chen ,  Margaret Karow

IPC分类号： C12N5/10 ,  C12N15/13 ,  C12N15/63 ,  C07K16/28 ,  A61K39/00

摘要： A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.

公开(公告)号：US10179819B2

公开(公告)日：2019-01-15

申请号：US15223434

申请日：2016-07-29

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Jessica R. Kirshner ,  Alison Crawford ,  Gavin Thurston ,  Eric Smith ,  Lauric Haber ,  Drew Dudgeon ,  Ashique Rafique

IPC分类号： A61K39/00 ,  C07K16/30 ,  C07K16/28 ,  A61K39/395

摘要： The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers.

公开(公告)号：US20140255995A1

公开(公告)日：2014-09-11

申请号：US14206259

申请日：2014-03-12

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： Sean Stevens ,  Tammy T. Huang ,  Joel H. Martin ,  Jeanette L. Fairhurst ,  Ashique Rafique ,  Eric Smith ,  Kevin J. Pobursky ,  Nicholas J. Papadopoulos ,  James P. Fandl ,  Gang Chen ,  Margaret Karow

IPC分类号： C07K16/28

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.

摘要翻译： 提供了以约500pM以下的KD结合人IL-6受体（hIL-6R）的人抗体或抗原结合片段，并且以200pM以下的IC 50阻断IL-6活性。 在优选的实施方案中，抗体抗体或抗原结合片段以相对于其结合猴IL-6R至少高2倍的亲和力结合hIL-6R。

公开(公告)号：US20230094591A1

公开(公告)日：2023-03-30

申请号：US17749728

申请日：2022-05-20

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： Sean Stevens ,  Tammy T. Huang ,  Joel H. Martin ,  Jeanette L. Fairhurst ,  Ashique Rafique ,  Eric Smith ,  Kevin J. Pobursky ,  Nicholas J. Papadopoulos ,  James P. Fandl ,  Gang Chen ,  Margaret Karow

IPC分类号： C07K16/28 ,  A61K39/00

摘要： A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.

公开(公告)号：US20190256606A1

公开(公告)日：2019-08-22

申请号：US16119695

申请日：2018-08-31

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： Sean Stevens ,  Tammy T. Huang ,  Joel H. Martin ,  Jeanette L. Fairhurst ,  Ashique Rafique ,  Eric Smith ,  Kevin J. Pobursky ,  Nicholas J. Papadopoulos ,  James P. Fandl ,  Gang Chen ,  Margaret Karow

IPC分类号： C07K16/28

摘要： A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.

公开(公告)号：US09308256B2

公开(公告)日：2016-04-12

申请号：US14020573

申请日：2013-09-06

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Allen Radin ,  Sean Stevens ,  Tammy T. Huang ,  Joel H. Martin ,  Jeanette L. Fairhurst ,  Ashique Rafique ,  Eric Smith ,  Kevin J. Pobursky ,  Nicholas J. Papadopoulos ,  James P. Fandl ,  Gang Chen ,  Margaret Karow

IPC分类号： A61K39/395 ,  A61K31/4706 ,  A61K31/519 ,  A61K31/655 ,  A61K38/19 ,  A61K45/06 ,  C07K16/28 ,  C07K16/24 ,  A61K39/00

CPC分类号： A61K39/3955 ,  A61K31/4706 ,  A61K31/519 ,  A61K31/655 ,  A61K38/191 ,  A61K39/39541 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/248 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  Y10S514/885 ,  A61K2300/00

摘要： The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.

公开(公告)号：US20240124613A1

公开(公告)日：2024-04-18

申请号：US18538999

申请日：2023-12-13

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Robert Babb ,  Ashique Rafique ,  Tammy T. Huang ,  Ergang Shi ,  Lynn Macdonald ,  Andrew J. Murphy

IPC分类号： C07K16/44 ,  A01K67/027 ,  C07K16/00 ,  C12N15/85 ,  G01N33/68

CPC分类号： C07K16/44 ,  A01K67/0275 ,  A01K67/0278 ,  C07K16/00 ,  C12N15/8509 ,  G01N33/6854 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/01 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/515 ,  C07K2317/569 ,  C07K2317/62 ,  C07K2317/92

摘要： Methods for making, identifying, isolating and/or making binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Exemplary binding proteins specific to small molecules are also provided.

公开(公告)号：US20200377618A1

公开(公告)日：2020-12-03

申请号：US16996302

申请日：2020-08-18

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Robert Babb ,  Ashique Rafique ,  Tammy T. Huang ,  Ergang Shi ,  Lynn Macdonald ,  Andrew J. Murphy

IPC分类号： C07K16/44 ,  C07K16/00 ,  A01K67/027 ,  C12N15/85 ,  G01N33/68

摘要： Methods for making, identifying, isolating and/or making binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Exemplary binding proteins specific to small molecules are also provided.